Brief: Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility
20/04/2026 13:02
April 20 (Reuters) - Gilead Sciences Inc GILD.O: ARCUS BIOSCIENCES INC - DISCONTINUES PHASE 3 STAR-121 STUDY WITH GILEAD DUE TO FUTILITY - SEC FILING ARCUS BIOSCIENCES INC - STAR-121 AND PHASE 2 EDGE-LUNG STUDIES TO BE DISCONTINUED - SEC FILING ARCUS BIOSCIENCES INC - GILEAD'S OPTION RIGHTS UNDER COLLABORATION AGREEMENT TO END JULY 14, 2026 - SEC FILING Source text: [ID:n0001724521-26-000021] Further company coverage: GILD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsArcus Biosciences Q1 revenue falls on lower development services
Brief: Arcus Biosciences Q1 Net Income USD -128 Million
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
Brief: Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility
Brief: Arcus Biosciences Files For Mixed Shelf